Search PubMed⌕ Search

Biomedical subjects

D L Murphy

Publications and source records attributed to D L Murphy.

At least 505 records · Page 28Linked to original sources
PubMed1978

Prediction of imipramine antidepressant response by a one-day dextro-amphetamine trial.

This study provides additional evidence that there is a moderate association between the acute activation, euphoria, and antidepressant responses to dextro-amphetamine and the antidepressant response to imipramine during a four-week trial. Comparison of the responses of 13 patients to dextro-amphetamine on two different days during a double blind trial indicated that differences in dextro-amphetamine response are consistent, replicable characteristics of individual depressed patients. The variables of sex, diagnosis, diurnal mood variation, platelet MAO activity, and MMPI scale scores were of minimal assistance in revealing factors that might be associated with activation or antidepressant responses to dextro-amphetamine in this small patient group. The authors suggest the need for larger-scale studies in this area.

Adolescent↗
PubMed1978

Prediction of antidepressant responses to lithium.

The authors studied 53 patients hospitalized for depression to evaluate possible associations between pretreatment responses to the Minnesota Multiphasic Personality Inventory and behaviorally rated responses to lithium. Patients were randomly assigned to two groups (A and B) in which responders and nonresponders were balanced for sex. For the 18 women in group A, a lithium response scale discriminated responders with 89% accuracy. For the 9 males, a separate scale discriminated responders with 100% accuracy. In a cross-validation, the two scales discriminated responders and nonresponders with 100% accuracy in group B. The empirical methodology of this study suggests an alternative to the theoretical-rational approach of predicting response to antidepressant drugs based on pretreatment depressive symptoms.

Adult↗
PubMed1978

MAO activity, csf amine metabolites, and drug-free improvement in schizophrenia.

Platelet monoamine oxidase (MAO) activity and amine metabolites in cerebrospinal fluid were compared in 22 schizophrenic patients, 8 of whom improved during a 30-day drug-free period. CSF 5-hydroxyindoleacetic acid and homovanillic acid did not distinguish between drug-free improvers and nonimprovers. However, drug-free improvers had lower platelet MAO activities than did normal controls. The authors suggest that looking at clinical variables in patients with low MAO activity might provide a means of biologically subtyping schizophrenic patients.

Adolescent↗
PubMed1978

Platelet and plasma amine oxidase activity in alcoholic individuals.

Platelet and plasma amine oxidase activity was determined in a group of 99 healthy male (active duty military) alcoholics referred for hospital treatment who had been abstinent from alcohol for 2-10 days, and compared with that of a control military group. Platelet MAO activity was slightly but significantly lower in the alcoholic group. Both groups were significantly lower in MAO activity compared to a group of 42 non-military controls. In the alcoholic group there was no correlation between platelet MAO and severity or chronicity of drinking, nor was there evidence of iron deficiency to account for the lowered MAO activity. When the alcoholic and military control groups were split at the median, the first degree relatives of both the 'low' MAO alcoholics and the 'low' MAO military controls had a higher incidence of alcoholism than did the relatives of both 'high' MAO subgroups. No personal or family history data of alcohol-related problems were available on the non-military control group.

Adult↗
PubMed1978

Comparison of the X537A-induced ionophoric removal of serotonin and tryptamine from intact human platelets.

In the absence of appreciable dense-body release from platelets, X537A causes rapid movement of 90--95% of vesicular H3-5HT into the extracellular medium. X537A can in addition transport to the extracellular medium 20% of the total tryptamine sequestered in platelets. Investigation of the extraction of aqueous 5HT and tryptamine into a chloroform phase, and the subsequent extraction of each of the two amines from a chloroform to an aqueous phase, suggest that 5HT, but not tryptamine, is transported efficiently between aqueous phases through a non-polar solvent. The observed differences in the movement of the two amines through platelet membranes may be attributable to a similar phenomenon.

Anti-Bacterial Agents↗
PubMed1977

Elevation of plasma-prolactin by monoamine-oxidase inhibitors.

Plasma-prolactin levels doubled in depressive patients treated with the monoamine-oxidase inhibitors, clorgyline and pargyline. The absence of significant changes in plasma-cortisol in the same patients suggests that the increases in prolactin are not attributable to non-specific effects of stress.

Clorgyline↗
PubMed1977

Individual differences in average evoked responses to d- and l-amphetamine with and without lithium carbonate in depressed patients.

Visual average evoked responses (AERs) to four intensities of light were studied in hospitalized depressed patients receiving placebo, d-amphetamine, l-amphetamine, lithium and d- and l-amphetamine combined with lithium. For the assessment of the subjective effects of the drugs, the patients completed a 34-item mood and behavior self-rating scale. AER responses to repeated doses of the amphetamines were consistent within the same individual but varied greatly between different individuals. For the patient group considered as a whole, only minor AER changes occurred in response to either d- or l-amphetamine; nonetheless, these minor changes were attenuated by lithium co-administration. There were indications, however, that AER baseline measures could be used as predictors of change in self-rating due to both d- and l-amphetamine, as patients who had larger AER amplitudes on baseline also tended to have larger increases in activation ratings and reductions in depression ratings. The amount of increase in AER amplitude or amplitude/intensity slope seen with amphetamine was also significantly correlated with the amount of increase in activation or euphoria ratings with amphetamine administration. These effects were most prominent in the same P100 component that we have previously found to differentiate bipolar and unipolar depressed patient groups.

Adult↗
PubMed1977

Increased norepinephrine levels and decreased dopamine-beta-hydroxylase activity in primary autism.

The sympathetic nervous system was evaluated in 11 primary autistic patients and their families. The plasma levels of norepinephrine (NE), the neurotransmitter of the sympathetic nervous system, was higher in the patients than in age-controlled normal volunteers both while supine and after standing. The plasma activity of dopamine-beta-hydroxylase, the enzyme that converts dopamine to NE, was significantly lower in the autistic patients and their healthy relatives than in control groups. Dopamine-beta-hydroxylase does not appear to provide an index of sympathetic activity in this group of patients who, on the basis of the elevated plasma levels of NE, may demonstrate a chronic state of hyperactivity of the sympathetic nervous system. Low enzyme activity found in both the autistic patients and their immediate families may be associated with this disorder.

Autistic Disorder↗
PubMed1977

Reduced MAO activity in first-degree relatives of individuals with bipolar affective disorders. A preliminary report.

Previous reports have indicated that platelet monoamine oxidase (MAO) activity is reduced in patients with the bipolar form of major affective illness. We present evidence that platelet MAO activity is also significantly reduced in the first-degree relatives of bipolar patients. However, platelet MAO activity did not distinguish ill from well family members. It is possible that reduced platelet MAO may be an indicator of increased familial vulnerability to affective disorders.

Adolescent↗
PubMed1977

Reduction in plasma norepinephrine during fenfluramine treatment.

Plasma norepinephrine levels were reduced to 30% of placebo levels during the administration of fenfluramine, 120 mg/day, for 10 or more days. There was also a significant reduction in plasma dopamine beta-hydroxylase activity during fenfluramine treatment, suggesting that chronic administration may induce antiadrenergic effects which may be useful in the treatment of disorders affected by circulating catecholamines.

Adult↗